Compass Therapeutics (CMPX) Competitors $3.49 +0.21 (+6.40%) Closing price 04:00 PM EasternExtended Trading$3.39 -0.10 (-2.87%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. AUPH, WVE, JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, and VERAShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors Aurinia Pharmaceuticals WAVE Life Sciences Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Is CMPX or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Compass Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -53.11% -46.14% Aurinia Pharmaceuticals 23.31%20.06%13.81% Does the media prefer CMPX or AUPH? In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 2 mentions for Compass Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.44 beat Compass Therapeutics' score of 0.93 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CMPX or AUPH? Compass Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Do insiders & institutionals believe in CMPX or AUPH? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, CMPX or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K567.76-$49.38M-$0.45-7.76Aurinia Pharmaceuticals$235.13M6.76$5.75M$0.4328.09 Do analysts prefer CMPX or AUPH? Compass Therapeutics presently has a consensus price target of $12.89, indicating a potential upside of 269.31%. Aurinia Pharmaceuticals has a consensus price target of $12.00, indicating a potential downside of 0.66%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAurinia Pharmaceuticals beats Compass Therapeutics on 9 of the 17 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$453.57M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-7.767.3622.5622.49Price / Sales567.76398.26463.84113.07Price / CashN/A44.6737.7359.36Price / Book5.218.0910.046.68Net Income-$49.38M-$54.08M$3.27B$265.59M7 Day Performance24.64%2.25%3.17%3.42%1 Month Performance9.06%3.41%4.34%1.09%1 Year Performance193.28%18.61%44.12%23.84% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.2155 of 5 stars$3.49+6.4%$12.89+269.3%+160.3%$453.57M$850K-7.7620AUPHAurinia Pharmaceuticals2.2545 of 5 stars$12.22-0.4%$12.00-1.8%+79.9%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.7744 of 5 stars$9.74-0.2%$20.27+108.1%+78.4%$1.55B$108.30M-10.82240Insider TradeJANXJanux Therapeutics2.5501 of 5 stars$25.53+1.7%$91.89+259.9%-48.3%$1.51B$10.59M-14.1830News CoveragePositive NewsEWTXEdgewise Therapeutics2.3223 of 5 stars$14.00-1.1%$41.60+197.1%-26.9%$1.49BN/A-9.0360Insider TradeARDXArdelyx4.1494 of 5 stars$5.81-2.7%$11.50+97.9%-0.5%$1.44B$333.61M-25.2690News CoverageInsider TradeHROWHarrow3.4486 of 5 stars$38.32-1.3%$64.67+68.8%-10.6%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4039 of 5 stars$14.03-3.4%$31.00+121.0%-3.7%$1.44B$89.15M-28.6390SDGRSchrodinger2.8538 of 5 stars$20.05+3.5%$27.83+38.8%-4.0%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.3919 of 5 stars$29.76-0.2%$31.50+5.8%-37.1%$1.39B$731.97M11.152,028News CoverageAnalyst ForecastVERAVera Therapeutics3.8314 of 5 stars$21.80+1.2%$63.00+189.0%-41.5%$1.37BN/A-6.0940News CoveragePositive News Related Companies and Tools Related Companies AUPH Alternatives WVE Alternatives JANX Alternatives EWTX Alternatives ARDX Alternatives HROW Alternatives SPRY Alternatives SDGR Alternatives AMPH Alternatives VERA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access